Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CCX025
- Development stage
- Discontinued
- Lead developer
- Amgen
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
CCX025 is an orally bioavailable small molecule antagonist of the C-C chemokine receptor type 9 (CCR9), developed by ChemoCentryx for the treatment of inflammatory bowel diseases (IBD) and other gastrointestinal disorders. CCR9 is a chemokine receptor predominantly expressed on gut-homing T cells, and its interaction with the ligand CCL25 (TECK) facilitates the migration of these cells into the intestinal mucosa. By selectively blocking CCR9, CCX025 aimed to inhibit the localized inflammatory response characteristic of conditions like Crohn's disease and ulcerative colitis. The drug was structurally distinct from ChemoCentryx's other CCR9 antagonist, vercirnon (Traficet-EN), and completed Phase I clinical testing for safety and pharmacokinetics before its development was discontinued.
02
Targets
CCR9 (C-C chemokine receptor type 9)
Beyond the preview
Go deeper on CCX025.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CCX025.